Your browser doesn't support javascript.
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.
McCallum, Matthew; Bassi, Jessica; De Marco, Anna; Chen, Alex; Walls, Alexandra C; Di Iulio, Julia; Tortorici, M Alejandra; Navarro, Mary-Jane; Silacci-Fregni, Chiara; Saliba, Christian; Sprouse, Kaitlin R; Agostini, Maria; Pinto, Dora; Culap, Katja; Bianchi, Siro; Jaconi, Stefano; Cameroni, Elisabetta; Bowen, John E; Tilles, Sasha W; Pizzuto, Matteo Samuele; Guastalla, Sonja Bernasconi; Bona, Giovanni; Pellanda, Alessandra Franzetti; Garzoni, Christian; Van Voorhis, Wesley C; Rosen, Laura E; Snell, Gyorgy; Telenti, Amalio; Virgin, Herbert W; Piccoli, Luca; Corti, Davide; Veesler, David.
  • McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Chen A; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Di Iulio J; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Navarro MJ; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Saliba C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Agostini M; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Tilles SW; Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
  • Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Guastalla SB; Independent physician, 6828 Balerna, Switzerland.
  • Bona G; Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
  • Pellanda AF; Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
  • Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
  • Van Voorhis WC; Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
  • Rosen LE; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Telenti A; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA.
  • Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. lpiccoli@vir.bio dcorti@vir.bio dveesler@uw.edu.
  • Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland. lpiccoli@vir.bio dcorti@vir.bio dveesler@uw.edu.
  • Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. lpiccoli@vir.bio dcorti@vir.bio dveesler@uw.edu.
Science ; 373(6555): 648-654, 2021 08 06.
Article in English | MEDLINE | ID: covidwho-1295161
ABSTRACT
A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429), which was originally detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal domain (NTD), and L452R in the receptor-binding domain (RBD). Plasma from individuals vaccinated with a Wuhan-1 isolate-based messenger RNA vaccine or from convalescent individuals exhibited neutralizing titers that were reduced 2- to 3.5-fold against the B.1.427/B.1.429 variant relative to wild-type pseudoviruses. The L452R mutation reduced neutralizing activity in 14 of 34 RBD-specific monoclonal antibodies (mAbs). The S13I and W152C mutations resulted in total loss of neutralization for 10 of 10 NTD-specific mAbs because the NTD antigenic supersite was remodeled by a shift of the signal peptide cleavage site and the formation of a new disulfide bond, as revealed by mass spectrometry and structural studies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immune Evasion / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Science Year: 2021 Document Type: Article Affiliation country: Science.abi7994

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immune Evasion / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Science Year: 2021 Document Type: Article Affiliation country: Science.abi7994